![Qiong Liu](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Qiong Liu
Direktor/Vorstandsmitglied bei Wuxi Langshion Lightweight Technology Co., Ltd.
Profil
Qiong Liu currently works at Wuxi Langshion Lightweight Technology Co., Ltd., as Director from 2021.
Aktive Positionen von Qiong Liu
Unternehmen | Position | Beginn |
---|---|---|
Wuxi Langshion Lightweight Technology Co., Ltd.
![]() Wuxi Langshion Lightweight Technology Co., Ltd. Investment Trusts/Mutual FundsMiscellaneous Wuxi Langshion Lightweight Technology Co., Ltd. is a leading biologics technology platform that offers end-to-end solutions for discovering, developing, and manufacturing biologics from concept to commercial manufacturing. The company is based in Wuxi, China. Wuxi Biologics is committed to environmental, social, and governance (ESG) responsibilities and aims to become an ESG leader in biologics manufacturing. It specializes in viral vaccines process development, microbial services, and solutions. The Chinese company uses next-generation clean biomanufacturing technologies and cleaner energy sources. It has also established an ESG committee led by the CEO, Yang Chen, who founded the company in 2013 and has been the CEO since then. | Direktor/Vorstandsmitglied | 24.12.2021 |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Private Unternehmen | 1 |
---|---|
Wuxi Langshion Lightweight Technology Co., Ltd.
![]() Wuxi Langshion Lightweight Technology Co., Ltd. Investment Trusts/Mutual FundsMiscellaneous Wuxi Langshion Lightweight Technology Co., Ltd. is a leading biologics technology platform that offers end-to-end solutions for discovering, developing, and manufacturing biologics from concept to commercial manufacturing. The company is based in Wuxi, China. Wuxi Biologics is committed to environmental, social, and governance (ESG) responsibilities and aims to become an ESG leader in biologics manufacturing. It specializes in viral vaccines process development, microbial services, and solutions. The Chinese company uses next-generation clean biomanufacturing technologies and cleaner energy sources. It has also established an ESG committee led by the CEO, Yang Chen, who founded the company in 2013 and has been the CEO since then. | Miscellaneous |